Fibrinolytic inhibitors for cancer-associated bleeding problems.
This pilot study of 16 patients explored the use of two fibrinolytic inhibitors, tranexamic acid and aminocaproic acid, for the suppression of tumor-associated hemorrhage. The effects of such bleeding include anemia requiring transfusion, practical difficulties with dressings, and psychological morbidity from constant reminder of poor physical health. Cessation of bleeding occurred in 14 of the 16 patients treated. The average time until significant improvement in bleeding was just 2 days and the average time for complete cessation was 4 days. We conclude that fibrinolytic inhibitors are potentially useful agents in palliative care.
Dean
A
A
Department of General Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Tuffin
P
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D010865:Pilot Projects
D000933:Antifibrinolytic Agents